Swedish biopharmaceutical company Alzinova received FDA approval to commence Phase II clinical trials for ALZ-101, a therapeutic vaccine targeting toxic amyloid-beta oligomers implicated in Alzheimer's disease pathogenesis. Building on favorable Phase Ib safety and immunogenicity data, this study will evaluate efficacy in a larger patient population, moving closer to a potential disease-modifying treatment option for Alzheimer's patients.